| . | Cryoballoon CA (n = 107) . | AAD (n = 111) . |
|---|---|---|
| Demographics and echocardiographic characteristics | ||
| Age (years) | 50.5 (13.1) | 54.1 (13.4) |
| Sex, male | 76 (71.0%) | 72 (64.9%) |
| Time from first ECG-documented AF to enrolment (years) | 0.7 (1.5) | 0.8 (2.1) |
| Left atrial diameter (short axis) (mm) | 37.0 (5.9) | 38.0 (4.9) |
| Left atrial diameter (long axis) (mm) | 46.8 (8.2) | 47.7 (6.3) |
| Left ventricular ejection fraction (%) | 62.8 (5.4) | 63.7 (5.4) |
| EHRA class | ||
| Class I | 0 (0.0%) | 0 (0.0%) |
| Class II | 75 (70.1%) | 83 (74.8%) |
| Class III | 30 (28.0%) | 25 (22.5%) |
| Class IV | 2 (1.9%) | 1 (0.9%) |
| Medical history | ||
| Hypertension | 33 (30.8%) | 40 (36.0%) |
| Diabetes | 1 (0.9%) | 4 (3.6%) |
| Hyperlipidaemia | 23 (21.5%) | 25 (22.5%) |
| Myocardial infarction | 2 (1.9%) | 0 (0.0%) |
| Coronary artery disease | 2 (1.9%) | 1 (0.9%) |
| Congestive heart failure | 0 (0.0%) | 0 (0.0%) |
| Stroke | 0 (0.0%) | 0 (0.0%) |
| Transient ischaemic attack | 0 (0.0%) | 1 (0.9%) |
| Valve dysfunction | 3 (2.8%) | 2 (1.8%) |
| CHA2DS2-VASc score | ||
| 0 | 49 (45.8%) | 38 (34.2%) |
| 1 | 33 (30.8%) | 40 (36.1%) |
| 2 | 13 (12.2%) | 15 (13.5%) |
| 3 | 4 (3.7%) | 10 (9.0%) |
| 4 | 3 (2.8%) | 2 (1.8%) |
| Baseline medications | ||
| Anticoagulant | 38 (35.5%) | 49 (44.1%) |
| Acetylsalicylic acid | 5 (4.7%) | 7 (6.3%) |
| β-Blocker | 54 (50.5%) | 56 (50.5%) |
| Calcium channel blocker | 9 (8.4%) | 15 (13.5%) |
| . | Cryoballoon CA (n = 107) . | AAD (n = 111) . |
|---|---|---|
| Demographics and echocardiographic characteristics | ||
| Age (years) | 50.5 (13.1) | 54.1 (13.4) |
| Sex, male | 76 (71.0%) | 72 (64.9%) |
| Time from first ECG-documented AF to enrolment (years) | 0.7 (1.5) | 0.8 (2.1) |
| Left atrial diameter (short axis) (mm) | 37.0 (5.9) | 38.0 (4.9) |
| Left atrial diameter (long axis) (mm) | 46.8 (8.2) | 47.7 (6.3) |
| Left ventricular ejection fraction (%) | 62.8 (5.4) | 63.7 (5.4) |
| EHRA class | ||
| Class I | 0 (0.0%) | 0 (0.0%) |
| Class II | 75 (70.1%) | 83 (74.8%) |
| Class III | 30 (28.0%) | 25 (22.5%) |
| Class IV | 2 (1.9%) | 1 (0.9%) |
| Medical history | ||
| Hypertension | 33 (30.8%) | 40 (36.0%) |
| Diabetes | 1 (0.9%) | 4 (3.6%) |
| Hyperlipidaemia | 23 (21.5%) | 25 (22.5%) |
| Myocardial infarction | 2 (1.9%) | 0 (0.0%) |
| Coronary artery disease | 2 (1.9%) | 1 (0.9%) |
| Congestive heart failure | 0 (0.0%) | 0 (0.0%) |
| Stroke | 0 (0.0%) | 0 (0.0%) |
| Transient ischaemic attack | 0 (0.0%) | 1 (0.9%) |
| Valve dysfunction | 3 (2.8%) | 2 (1.8%) |
| CHA2DS2-VASc score | ||
| 0 | 49 (45.8%) | 38 (34.2%) |
| 1 | 33 (30.8%) | 40 (36.1%) |
| 2 | 13 (12.2%) | 15 (13.5%) |
| 3 | 4 (3.7%) | 10 (9.0%) |
| 4 | 3 (2.8%) | 2 (1.8%) |
| Baseline medications | ||
| Anticoagulant | 38 (35.5%) | 49 (44.1%) |
| Acetylsalicylic acid | 5 (4.7%) | 7 (6.3%) |
| β-Blocker | 54 (50.5%) | 56 (50.5%) |
| Calcium channel blocker | 9 (8.4%) | 15 (13.5%) |
Values are n (%) or mean (standard deviation).
AAD, antiarrhythmic drug; AF, atrial fibrillation; CA, catheter ablation; EHRA, European Heart Rhythm Association score.
| . | Cryoballoon CA (n = 107) . | AAD (n = 111) . |
|---|---|---|
| Demographics and echocardiographic characteristics | ||
| Age (years) | 50.5 (13.1) | 54.1 (13.4) |
| Sex, male | 76 (71.0%) | 72 (64.9%) |
| Time from first ECG-documented AF to enrolment (years) | 0.7 (1.5) | 0.8 (2.1) |
| Left atrial diameter (short axis) (mm) | 37.0 (5.9) | 38.0 (4.9) |
| Left atrial diameter (long axis) (mm) | 46.8 (8.2) | 47.7 (6.3) |
| Left ventricular ejection fraction (%) | 62.8 (5.4) | 63.7 (5.4) |
| EHRA class | ||
| Class I | 0 (0.0%) | 0 (0.0%) |
| Class II | 75 (70.1%) | 83 (74.8%) |
| Class III | 30 (28.0%) | 25 (22.5%) |
| Class IV | 2 (1.9%) | 1 (0.9%) |
| Medical history | ||
| Hypertension | 33 (30.8%) | 40 (36.0%) |
| Diabetes | 1 (0.9%) | 4 (3.6%) |
| Hyperlipidaemia | 23 (21.5%) | 25 (22.5%) |
| Myocardial infarction | 2 (1.9%) | 0 (0.0%) |
| Coronary artery disease | 2 (1.9%) | 1 (0.9%) |
| Congestive heart failure | 0 (0.0%) | 0 (0.0%) |
| Stroke | 0 (0.0%) | 0 (0.0%) |
| Transient ischaemic attack | 0 (0.0%) | 1 (0.9%) |
| Valve dysfunction | 3 (2.8%) | 2 (1.8%) |
| CHA2DS2-VASc score | ||
| 0 | 49 (45.8%) | 38 (34.2%) |
| 1 | 33 (30.8%) | 40 (36.1%) |
| 2 | 13 (12.2%) | 15 (13.5%) |
| 3 | 4 (3.7%) | 10 (9.0%) |
| 4 | 3 (2.8%) | 2 (1.8%) |
| Baseline medications | ||
| Anticoagulant | 38 (35.5%) | 49 (44.1%) |
| Acetylsalicylic acid | 5 (4.7%) | 7 (6.3%) |
| β-Blocker | 54 (50.5%) | 56 (50.5%) |
| Calcium channel blocker | 9 (8.4%) | 15 (13.5%) |
| . | Cryoballoon CA (n = 107) . | AAD (n = 111) . |
|---|---|---|
| Demographics and echocardiographic characteristics | ||
| Age (years) | 50.5 (13.1) | 54.1 (13.4) |
| Sex, male | 76 (71.0%) | 72 (64.9%) |
| Time from first ECG-documented AF to enrolment (years) | 0.7 (1.5) | 0.8 (2.1) |
| Left atrial diameter (short axis) (mm) | 37.0 (5.9) | 38.0 (4.9) |
| Left atrial diameter (long axis) (mm) | 46.8 (8.2) | 47.7 (6.3) |
| Left ventricular ejection fraction (%) | 62.8 (5.4) | 63.7 (5.4) |
| EHRA class | ||
| Class I | 0 (0.0%) | 0 (0.0%) |
| Class II | 75 (70.1%) | 83 (74.8%) |
| Class III | 30 (28.0%) | 25 (22.5%) |
| Class IV | 2 (1.9%) | 1 (0.9%) |
| Medical history | ||
| Hypertension | 33 (30.8%) | 40 (36.0%) |
| Diabetes | 1 (0.9%) | 4 (3.6%) |
| Hyperlipidaemia | 23 (21.5%) | 25 (22.5%) |
| Myocardial infarction | 2 (1.9%) | 0 (0.0%) |
| Coronary artery disease | 2 (1.9%) | 1 (0.9%) |
| Congestive heart failure | 0 (0.0%) | 0 (0.0%) |
| Stroke | 0 (0.0%) | 0 (0.0%) |
| Transient ischaemic attack | 0 (0.0%) | 1 (0.9%) |
| Valve dysfunction | 3 (2.8%) | 2 (1.8%) |
| CHA2DS2-VASc score | ||
| 0 | 49 (45.8%) | 38 (34.2%) |
| 1 | 33 (30.8%) | 40 (36.1%) |
| 2 | 13 (12.2%) | 15 (13.5%) |
| 3 | 4 (3.7%) | 10 (9.0%) |
| 4 | 3 (2.8%) | 2 (1.8%) |
| Baseline medications | ||
| Anticoagulant | 38 (35.5%) | 49 (44.1%) |
| Acetylsalicylic acid | 5 (4.7%) | 7 (6.3%) |
| β-Blocker | 54 (50.5%) | 56 (50.5%) |
| Calcium channel blocker | 9 (8.4%) | 15 (13.5%) |
Values are n (%) or mean (standard deviation).
AAD, antiarrhythmic drug; AF, atrial fibrillation; CA, catheter ablation; EHRA, European Heart Rhythm Association score.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
